One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Gracell Biotechnologies  logo
Gracell Biotechnologies GRCL
report update icon

Quarterly report 2023-Q2
added 05-23-2026

Gracell Biotechnologies Income Statement 2022-2011 | GRCL

Annual Income Statement Gracell Biotechnologies

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

- 1.99 B - - - - - - - - - -

Shares

338 M 329 M 99 M 99.1 M 100 B - - - - - - -

Historical Prices

- 6.04 - - - - - - - - - -

Net Income

-608 M -452 M -212 M -139 M -60.8 M - - - - - - -

Operating Income

-625 M -464 M -214 M -147 M -62.5 M - - - - - - -

Interest Expense

6.74 M 5.06 M 2.16 M -21 K 20 K - - - - - - -

EBITDA

-566 M -419 M -193 M -141 M -59.5 M - - - - - - -

Operating Expenses

- - 214 M 147 M 62.5 M - - - - - - -

General and Administrative Expenses

139 M 137 M 45.6 M 27.4 M 10.3 M - - - - - - -

All numbers in CNY currency

Quarterly Income Statement Gracell Biotechnologies

2023-Q2 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

340 M 338 M - 338 M - 329 M - - - 99 M - - - 99.1 M - - - 100 B - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-299 M -608 M - -305 M - -452 M - - - -212 M - - - -139 M - - - -60.8 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-308 M -625 M - -306 M - -464 M - - - -214 M - - - -147 M - - - -62.5 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

3.36 M 6.74 M - 3.08 M - 5.06 M - - - 2.16 M - - - -21 K - - - 20 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-282 M -566 M - -272 M - -419 M - - - -193 M - - - -141 M - - - -59.5 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

66.4 M 139 M - 66.7 M - 137 M - - - 45.6 M - - - 27.4 M - - - 10.3 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in CNY currency

The income statement is one of the three key financial reports of a company Gracell Biotechnologies (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
SELLAS Life Sciences Group SELLAS Life Sciences Group
SLS
$ 9.98 4.02 % $ 1.09 B usaUSA
Protara Therapeutics Protara Therapeutics
TARA
$ 2.32 1.46 % $ 99.4 M usaUSA
Relay Therapeutics Relay Therapeutics
RLAY
$ 16.28 1.41 % $ 2.79 B usaUSA
Pfizer Pfizer
PFE
$ 29.58 0.54 % $ 168 B usaUSA
Supernus Pharmaceuticals Supernus Pharmaceuticals
SUPN
$ 37.88 0.5 % $ 2.14 B usaUSA
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
TAK
$ 19.67 1.08 % $ 31.1 B japanJapan
Revolution Medicines Revolution Medicines
RVMD
$ 177.96 0.22 % $ 33.8 B usaUSA
Rhythm Pharmaceuticals Rhythm Pharmaceuticals
RYTM
$ 86.17 0.6 % $ 5.6 B usaUSA
Prelude Therapeutics Incorporated Prelude Therapeutics Incorporated
PRLD
$ 3.26 0.9 % $ 251 M usaUSA
Sana Biotechnology Sana Biotechnology
SANA
$ 2.27 6.22 % $ 575 M usaUSA
Pulmatrix Pulmatrix
PULM
$ 1.36 4.61 % $ 4.97 B usaUSA
Zoetis Zoetis
ZTS
$ 79.38 1.22 % $ 35.2 B usaUSA
Ultragenyx Pharmaceutical Ultragenyx Pharmaceutical
RARE
$ 14.54 1.81 % $ 1.43 B usaUSA
XTL Biopharmaceuticals Ltd. XTL Biopharmaceuticals Ltd.
XTLB
$ 1.96 2.62 % $ 1.32 B israelIsrael
Cleveland BioLabs, Inc. Cleveland BioLabs, Inc.
CBLI
- -7.31 % $ 49 M usaUSA
Zymeworks Zymeworks
ZYME
$ 25.03 0.16 % $ 1.29 B canadaCanada
AC Immune SA AC Immune SA
ACIU
$ 2.39 2.08 % $ 241 M schweizSchweiz
Five Prime Therapeutics, Inc. Five Prime Therapeutics, Inc.
FPRX
- - $ 1.77 B usaUSA
Adagene Adagene
ADAG
$ 2.06 4.8 % $ 122 M chinaChina
Adial Pharmaceuticals Adial Pharmaceuticals
ADIL
$ 3.49 11.15 % $ 2.33 M usaUSA
ADC Therapeutics SA ADC Therapeutics SA
ADCT
$ 1.4 0.34 % $ 178 M schweizSchweiz
ADMA Biologics ADMA Biologics
ADMA
$ 10.68 3.77 % $ 2.55 B usaUSA
Assembly Biosciences Assembly Biosciences
ASMB
$ 20.09 0.19 % $ 225 M usaUSA
Allogene Therapeutics Allogene Therapeutics
ALLO
$ 1.31 3.08 % $ 289 M usaUSA
Amgen Amgen
AMGN
$ 432.49 0.08 % $ 233 B usaUSA
Ardelyx Ardelyx
ARDX
$ 3.09 2.51 % $ 745 M usaUSA
Armata Pharmaceuticals Armata Pharmaceuticals
ARMP
$ 3.37 9.06 % $ 122 M usaUSA
Artelo Biosciences Artelo Biosciences
ARTL
$ 2.7 0.36 % $ 511 K usaUSA
Biofrontera AG Biofrontera AG
BFRA
- -8.24 % $ 105 M germanyGermany
Bicycle Therapeutics plc Bicycle Therapeutics plc
BCYC
$ 3.46 2.56 % $ 240 M britainBritain
Catabasis Pharmaceuticals, Inc. Catabasis Pharmaceuticals, Inc.
CATB
- -6.97 % $ 657 M usaUSA
Beam Therapeutics Beam Therapeutics
BEAM
$ 23.47 4.57 % $ 2.32 B usaUSA
China Biologic Products Holdings, Inc. China Biologic Products Holdings, Inc.
CBPO
- 1.68 % $ 4.65 B chinaChina
Benitec Biopharma Benitec Biopharma
BNTC
$ 8.11 2.05 % $ 378 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 87.71 1.74 % $ 21.2 B germanyGermany
ANI Pharmaceuticals ANI Pharmaceuticals
ANIP
$ 72.29 0.01 % $ 1.45 B usaUSA
C4 Therapeutics C4 Therapeutics
CCCC
$ 2.77 0.36 % $ 230 M usaUSA
Cerus Corporation Cerus Corporation
CERS
$ 2.18 0.66 % $ 415 M usaUSA
Certara Certara
CERT
$ 9.37 0.26 % $ 1.5 B usaUSA
Flexion Therapeutics, Inc. Flexion Therapeutics, Inc.
FLXN
- - $ 459 M usaUSA
Coherus BioSciences Coherus BioSciences
CHRS
$ 0.99 1.9 % $ 116 M usaUSA
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
CORT
$ 110.16 0.47 % $ 11.4 B usaUSA
CorMedix CorMedix
CRMD
$ 7.26 0.95 % $ 523 K usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
$ 49.25 2.59 % $ 4.43 B schweizSchweiz
Greenwich LifeSciences Greenwich LifeSciences
GLSI
$ 14.55 1.48 % $ 197 M usaUSA
Champions Oncology Champions Oncology
CSBR
$ 4.7 0.94 % $ 65 M usaUSA
Heat Biologics, Inc. Heat Biologics, Inc.
HTBX
- -5.76 % $ 99.8 M usaUSA
Cue Biopharma Cue Biopharma
CUE
$ 16.71 0.38 % $ 1.58 B usaUSA
Kindred Biosciences, Inc. Kindred Biosciences, Inc.
KIN
- 0.11 % $ 419 M usaUSA
DBV Technologies S.A. DBV Technologies S.A.
DBVT
$ 9.05 2.71 % $ 1.26 B franceFrance